Two Sigma Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,132,560
| Closed | -$450M | – | 90 |
|
|
2025
Q4 | $450M | Buy |
1,132,560
+240,060
| +27% | +$106M | 0.88% | 25 |
|
|
2025
Q3 | $407M | Buy |
892,500
+626,400
| +235% | +$255M | 0.81% | 23 |
|
|
2025
Q2 | $86.8M | Sell |
266,100
-9,700
| -4% | -$2.68M | 0.18% | 125 |
|
|
2025
Q1 | $74.5M | Buy |
275,800
+197,000
| +250% | +$50.6M | 0.17% | 126 |
|
|
2024
Q4 | $18.5M | Sell |
78,800
-24,300
| -24% | -$6.39M | 0.04% | 337 |
|
|
2024
Q3 | $28.4M | Sell |
103,100
-155,600
| -60% | -$40.5M | 0.07% | 252 |
|
|
2024
Q2 | $62.9M | Buy |
258,700
+69,100
| +36% | +$10.9M | 0.14% | 140 |
|
|
2024
Q1 | $28.3M | Buy |
+189,600
| New | +$31.6M | 0.07% | 271 |
|
|
2023
Q4 | – | Sell |
-35,900
| Closed | -$6.36M | – | 2486 |
|
|
2023
Q3 | $6.36M | Sell |
35,900
-157,700
| -81% | -$30.1M | 0.02% | 631 |
|
|
2023
Q2 | $36.8M | Buy |
193,600
+38,500
| +25% | +$7.63M | 0.09% | 214 |
|
|
2023
Q1 | $31.1M | Buy |
155,100
+35,100
| +29% | +$7.38M | 0.08% | 235 |
|
|
2022
Q4 | $28.5M | Buy |
120,000
+56,200
| +88% | +$12M | 0.08% | 247 |
|
|
2022
Q3 | $12.8M | Buy |
63,800
+51,400
| +415% | +$9.8M | 0.04% | 436 |
|
|
2022
Q2 | $1.81M | Sell |
12,400
-34,300
| -73% | -$4.87M | 0.01% | 1269 |
|
|
2022
Q1 | $7.63M | Buy |
46,700
+42,900
| +1,129% | +$6.54M | 0.02% | 624 |
|
|
2021
Q4 | $644K | Buy |
+3,800
| New | +$706K | ﹤0.01% | 1781 |
|
|
2021
Q2 | – | Sell |
-31,900
| Closed | -$4.5M | – | 2434 |
|
|
2021
Q1 | $4.5M | Buy |
31,900
+28,200
| +762% | +$4.24M | 0.01% | 891 |
|
|
2020
Q4 | $481K | Buy |
+3,700
| New | +$494K | ﹤0.01% | 1878 |
|
|
2020
Q3 | – | Sell |
-8,300
| Closed | -$1.23M | – | 2384 |
|
|
2020
Q2 | $1.23M | Buy |
+8,300
| New | +$1.12M | ﹤0.01% | 1474 |
|
|
2019
Q2 | – | Sell |
-70,800
| Closed | -$6.62M | – | 2298 |
|
|
2019
Q1 | $6.62M | Sell |
70,800
-46,300
| -40% | -$3.87M | 0.02% | 748 |
|
|
2018
Q4 | $8.54M | Sell |
117,100
-72,400
| -38% | -$5.57M | 0.02% | 613 |
|
|
2018
Q3 | $16.6M | Sell |
189,500
-44,322
| -19% | -$4.46M | 0.04% | 442 |
|
|
2018
Q2 | $23M | Sell |
233,822
-123,400
| -35% | -$12.2M | 0.06% | 360 |
|
|
2018
Q1 | $42.5M | Buy |
357,222
+248,200
| +228% | +$32M | 0.12% | 228 |
|
|
2017
Q4 | $13.9M | Buy |
+109,022
| New | +$13.7M | 0.04% | 498 |
|
|
2016
Q2 | – | Sell |
-101,622
| Closed | -$6.38M | – | 2039 |
|
|
2016
Q1 | $6.38M | Buy |
101,622
+97,300
| +2,251% | +$6.47M | 0.04% | 447 |
|
|
2015
Q4 | $407K | Buy |
+4,322
| New | +$401K | ﹤0.01% | 1404 |
|
|
2015
Q3 | – | Sell |
-5,022
| Closed | -$602K | – | 1794 |
|
|
2015
Q2 | $602K | Sell |
5,022
-1,500
| -23% | -$179K | ﹤0.01% | 1354 |
|
|
2015
Q1 | $681K | Sell |
6,522
-900
| -12% | -$91.2K | 0.01% | 1220 |
|
|
2014
Q4 | $720K | Buy |
+7,422
| New | +$688K | 0.01% | 1364 |
|
Other funds holding ALNY
VPM
VCM
Two Sigma Advisers's ALNY Position: Q1 2026 in Review
Two Sigma Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,132,560 shares — an estimated $450M sold.
Two Sigma Advisers first reported a position in ALNY in Q4 2014 and held it in 30 quarters. The position peaked at $450M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Two Sigma Advisers reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 1,132,560 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $450M.
- Two Sigma Advisers first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 30 quarters.
- Two Sigma Advisers's Alnylam Pharmaceuticals position peaked at $450M in Q4 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.